Talk:Paliperidone

From Wikipedia, the free encyclopedia

	This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess.
Stub	rated as stub-Class on the assessment scale
???	This article has not yet received an importance rating on the assessment scale.

Paliperidone is the brand name of an extended release formula of the longer acting 9-hydroxy metabolite of the antipsychotic known as Risperidone. Since some of the activity of risperidone is due to this active metabolite, one would expect there to be many similarities in effiacy and adverse effects between risperidone and paliperidone. Since it is a new and unique compound, it is still given patent protection. It is unclear as of yet what advantages, if any, it has over the parent compound. Since some of the effects of risperidone are due to the actual "parent" drug, there may be some differences between the two drugs but it is unclear as of yet whether or not this is the case. It is due to be released by or in early 2007.

Paliperidone is the major active metabolite of risperidone, it is differentiated from risperidone by the addition of one hydroxy group. It is certainly going to be licenced/marketed as a different drug and will nicely provide Janssen with a patented drug once Risperdal loses its. Colin°^Talk 20:18, 4 June 2006 (UTC)

That's a common enough technique for trying to extend patent protection. If we are sure the drug is confirmed then I guess it can have its own page; it needs the info box with the proper structure and prominent links to risperidone. However, since all the prescribing and side-effect info will the same at least for a few years (until and if paliperidone turns out to have different effects when its in wide use) it would still also make sense to keep it in one article. I guess I could go either way. Thatcher131 05:30, 5 June 2006 (UTC)